Autopsy report · NCT01913444

Pharmacokinetic Study of Recombinant AT III in Neonates Undergoing ECMO

“Unable to enroll patients into study.”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 4

Sponsor

Children's Hospital Los Angeles

Sponsor type

University, hospital or other

Conditions

Neonates on ECMO

Interventions

Recombinant Antithrombin

Participants

0

Sites

1

Countries

United States

Trials that died the same way

• Discharge Counseling and Medication Therapy Management (MTM) Services After Discharge for Heart Failure Patients
  “Unable to enroll and study intended patient population.” (91% match in meaning)
• Comparison of Three Approaches of Electrode Placement to Detect Changes in Motor Evoked Potentials During Spine Surgery
  “Unable to enroll patients.” (88% match in meaning)
• Evaluation of the Efficacy of Bio-K+ Cl-1285® In the Nasal Decolonization of Methicillin Resistant Staphylococcus Aureus (MRSA) Carrier Patients
  “Unable to recruit patients to continue on with the study.” (83% match in meaning)
• Slings and Their Effect on Skin Pressure
  “unable to recruit patients for study” (80% match in meaning)
• Acthar as Rescue Therapy for Transplant Glomerulopathy in Kidney Transplant Recipients
  “Unable to enroll patients, no longer at institution.” (80% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.